Impedimed Limited · ASX:IPD
Impedimed — Investor Presentation (July 2015)
24 slides from Impedimed's investor presentation, Jul 16, 2015
Slide 1: Investor Update July 2015
For personal use only Investor Update ASX:IPD July 2015
Slide 2: Disclaimer
Disclaimer For personal use only The material contained in this document is a presentation of general information about the activities of ImpediMed Limited (“ImpediMed”) current as at the date of this presentation. The information is provided in a summary form, does not purport to be complete and sh
Slide 3: Investment Summary
Investment Summary For personal use only IPD’s bioimpedance spectroscopy (BIS) — provides a simple, non-invasive system for accurately measuring tissue composition and fluid status First product, L-Dex®, allows early identification of lymphoedema — affects approximately 20% — 30% of cancer survivors
Slide 4: Corporate Overview
Corporate Overview For personal use only • ASX listed (October 2007) Share Price Performance – 12 Month (14 July 2015) • S&P/ASX 300 – added March 2015 • Operations in US (San Diego) and Aus (Brisbane) • 43 FTE staff • Market capitalisation ~$243M (~293M shares on issue) • Cash on hand $32.6M (30 Ju
Slide 5: Financial Year to Date (30 June)
Financial Year to Date (30 June) For personal use only 30 June (preliminary and FY2015 FY2014 % Change unaudited) $000 $000 Lymphoedema Revenue 2,043 1,594 28% ↑ Body Composition Revenue 968 891 9% ↑ Test & Measurement Revenue 1,832 1,036 77% ↑ Total Group Revenue 4,843 3,521 38% ↑ Operating Expense
Slide 6: Core Technology – Simple Method for Measuring Fluid and Tissue Composition
Core Technology – Simple Method for Measuring Fluid and Tissue Composition For personal use only Bioimpedance spectroscopy — a rapid, non-invasive system that provides highly accurate data Low Frequency Fluid Unique Spectra Impedance Fat Current passes around cells High Frequency Muscle 256 Frequenc
Slide 7: Clinical Benefits Of Knowing Fluid Balance and Tissue Composition
Clinical Benefits Of Knowing Fluid Balance and Tissue Composition For personal use only • Fluid imbalance has significant clinical implications • Detailed knowledge of fluid levels are highly informative: • Chronic swelling, lymphoedema, cardiovascular complications, etc. • Identify heart failure an
Slide 8: First Application – L-Dex for the Early Detection of Lymphoedema
First Application – L-Dex for the Early Detection of Lymphoedema For personal use only Simple and accurate measurement of fluid in limbs allows early detection and intervention 1. Treatment for cancer can damage the lymphatic system and result in fluid build up in the extremities 2. L-Dex is able to
Slide 9: A “Game Changing” Technology
A “Game Changing” Technology For personal use only • Informative – 256 frequency spectra provides detailed measurements of muscle, fluid, and fat • Simple to Use – easy placement of electrodes • Fast – 5-10 mins to measure • Non-invasive – no dyes or radiation • Safe – no safety concerns reported af
Slide 10: L-Dex Commercialisation Underway
L-Dex Commercialisation Underway For personal use only • L-Dex has regulatory approval in many major markets: • FDA clearance in US • TGA in Australia • CE Mark in Europe • Certificate of listing in Hong Kong • US Medicare reimbursement in place — L-Dex awarded a unique, dedicated CPT Category I cod
Slide 11: Potential Revenue Model for L-Dex
Potential Revenue Model for L-Dex For personal use only Annual US Relevant Cancer Incidences1 939,000 Patient Testing Protocols (assuming $112 per reading - National Payment Amount) Per Patient Year 1 Year 2 Year 3 Year 4 Year 5 Total Readings 5 1-4 1-4 1-2 0-2 8 - 17 Revenue $560 $112-$448 $112-$44
Slide 12: Cancer Centre Pilots Underway
Cancer Centre Pilots Underway For personal use only • Initial focus in US is on maximising adoption by select, large, leading cancer centres • Targeting 6 major cancer centres over 12 months • 4 oncology pilots underway • 2 multidisciplinary pilots commenced • Establish best practices to maximise ad
Slide 13: US Targeted Launch Update
US Targeted Launch Update For personal use only Update • 6 pilots underway, (4 oncology and 2 multidisciplinary centres) • Meeting our initial launch objectives • 2 pilots will be expanding their programs to other facilities • 2 pilots have integrated L-Dex into their electronic medical records (EMR
Slide 14: L-Dex Already Incorporated into Clinical Guidelines
L-Dex Already Incorporated into Clinical Guidelines For personal use only • Key position statements on early detection of lymphoedema — recommendations for BIS • Australasian Lymphology Association (ALA), Aus • National Lymphedema Network (NLN), US • National Accreditation Program for Breast Centres
Slide 15: Aim to have BIS Included In NCCN Guidelines
® Aim to have BIS Included In NCCN Guidelines For personal use only NCCN Guidelines® – are the recognised standard for clinical policy in cancer care in the US • Inclusion of BIS would make L-Dex the standard-of-care Recent Favourable Inclusions (First time lymphoedema included in Breast Cancer Guid
Slide 16: Guidelines - Significant Opportunity
Guidelines - Significant Opportunity For personal use only Lymphoedema being included in the guidelines is significant • Guidelines have now formally recognised lymphoedema as a major, long- term, chronic disease that needs to be addressed • Most centres use guidelines in their care pathways • Each
Slide 17: Outstanding Support For Post-Market Approval Trial
Outstanding Support For Post-Market Approval Trial For personal use only • 1,100 patient multicentre, randomised controlled study (Level I Evidence) • ~20% enrolled • On track for interim data release late CY2016/early CY2017 • Early detection of lymphoedema using BIS allows early treatment which pr
Slide 18: Independent Clinical Trials Also Underway/Completed
Independent Clinical Trials Also Underway/ Completed For personal use only United States • 2 trials (n ~100 each site) at large teaching hospitals • Recently published 180 patient trial results — BIS reduced clinical lymphoedema rate from 36.4% to 4.4% • Expecting second trial results later this cal
Slide 19: Platform Technology — Potential Applications and Markets
Platform Technology — Potential Applications and Markets For personal use only • BIS is a platform technology for precise measurements of tissue composition and fluid balance • Current focus is on commercialisation of first product; L-Dex for early detection of lymphoedema in cancer survivors • Pote
Slide 20: Strong News Flow Over Next Months
Strong News Flow Over Next 12 Months For personal use only • Regular updates on commercial usage and adoption of L-Dex • Further data from independent clinical trials • Progress on additional cancer guideline submissions • Ongoing development of new BIS opportunities • Full US commercial launch of L
Slide 21: Thank You
For personal use only Thank You
Slide 22: Appendix
For personal use only Appendix
Slide 23: Management Team Has Deep and Broad Commercialisation Experience
Management Team Has Deep and Broad Commercialisation Experience Rick Carreon •Joined July 2012 Managing Director and Chief •30+ years experience For personal use only Executive Officer •Extensive experience in the medical device field and growth companies •Previously Vice President at Medtronic (10
Slide 24: Board of Directors
Board of Directors Cherrell Hirst AO •On Board since 2005 FTSE, MBBS, BEdSt, D.Univ •Appointed Non-Executive Chairman in Nov 2011 For personal use only (Hon), FAICD •Leading medical practitioner in breast cancer screening/diagnosis Non-Executive Chairman •Currently interim Chairman of the Board of T